دورية أكاديمية
أعرض في EDS

Impact of COVID-19 on Cancer Care Delivery in Africa: A Cross-Sectional Survey of Oncology Providers in Africa.

التفاصيل البيبلوغرافية
العنوان: Impact of COVID-19 on Cancer Care Delivery in Africa: A Cross-Sectional Survey of Oncology Providers in Africa.
المؤلفون: Martei YM; Department of Medicine (Hematology-Oncology), University of Pennsylvania, Philadelphia, PA., Rick TJ; Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Fadelu T; Dana-Farber Cancer Institute, Boston, MA., Ezzi MS; University of Nairobi, Nairobi, Kenya., Hammad N; Queen's University Cancer Center of Southeastern Ontario, Kingston Health Science Center, Kingston, ON, Canada., Quadri NS; Allina Health, St Paul, MN., Rodrigues B; African Organization for Research and Training in Cancer, Cape Town, South Africa., Simonds H; Division of Radiation Oncology, Medical Imaging and Clinical Oncology, Tygerberg Academic Hospital, Cape Town, South Africa., Grover S; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA., Incrocci L; Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Vanderpuye V; National Center for Radiotherapy and Nuclear Medicine, Korle-Bu Teaching Hospital, Accra, Ghana.
المصدر: JCO global oncology [JCO Glob Oncol] 2021 Mar; Vol. 7, pp. 368-377.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101760170 Publication Model: Print Cited Medium: Internet ISSN: 2687-8941 (Electronic) Linking ISSN: 26878941 NLM ISO Abbreviation: JCO Glob Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2020]-
مواضيع طبية MeSH: COVID-19* , Neoplasms*/epidemiology , Neoplasms*/therapy, Delivery of Health Care/*organization & administration, Africa/epidemiology ; Cross-Sectional Studies ; Humans ; Pandemics
مستخلص: Purpose: The COVID-19 pandemic has disrupted cancer care globally. There are limited data of its impact in Africa. This study aims to characterize COVID-19 response strategies and impact of COVID-19 on cancer care and explore misconceptions in Africa.
Methods: We conducted a web-based cross-sectional survey of oncology providers in Africa between June and August 2020. Descriptive statistics and comparative analysis by income groups were performed.
Results: One hundred twenty-two participants initiated the survey, of which 79 respondents from 18 African countries contributed data. Ninety-four percent (66 of 70) reported country mitigation and suppression strategies, similar across income groups. Unique strategies included courier service and drones for delivery of cancer medications (9 of 70 and 6 of 70, respectively). Most cancer centers remained open, but > 75% providers reported a decrease in patient volume. Not previously reported is the fear of infectivity leading to staff shortages and decrease in patient volumes. Approximately one third reported modifications of all cancer treatment modalities, resulting in treatment delays. A majority of participants reported ≤ 25 confirmed cases (44 of 68, 64%) and ≤ 5 deaths because of COVID-19 (26 of 45, 58%) among patients with cancer. Common misconceptions were that Africans were less susceptible to the virus (53 of 70, 75.7%) and decreased transmission of the virus in the African heat (44 of 70, 62.9%).
Conclusion: Few COVID-19 cases and deaths were reported among patients with cancer. However, disruptions and delays in cancer care because of the pandemic were noted. The pandemic has inspired tailored innovative solutions in clinical care delivery for patients with cancer, which may serve as a blueprint for expanding care and preparing for future pandemics. Ongoing public education should address COVID-19 misconceptions. The results may not be generalizable to the entire African continent because of the small sample size.
References: JCO Glob Oncol. 2020 Jun;6:799-808. (PMID: 32511066)
JCO Glob Oncol. 2020 Sep;6:1428-1438. (PMID: 32986516)
BMJ Glob Health. 2020 Oct;5(10):. (PMID: 33028699)
JAMA Oncol. 2020 Jul 1;6(7):1108-1110. (PMID: 32211820)
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057. (PMID: 32267833)
Clin Colorectal Cancer. 2020 Sep;19(3):178-190.e1. (PMID: 32653470)
Lancet Oncol. 2020 May;21(5):621-622. (PMID: 32251623)
S Afr Med J. 2020 Apr 23;110(6):456-457. (PMID: 32880550)
Science. 2020 Jul 24;369(6502):413-422. (PMID: 32532802)
Infect Agent Cancer. 2019 May 21;14:11. (PMID: 31139248)
Curr Oncol. 2020 Apr;27(2):71-74. (PMID: 32489248)
Ecancermedicalscience. 2020 May 18;14:1047. (PMID: 32565900)
J Glob Oncol. 2018 Sep;(4):1-11. (PMID: 29244632)
Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. (PMID: 32573903)
Am J Clin Oncol. 2020 Jun;43(6):452-455. (PMID: 32304435)
Ann Oncol. 2020 Oct;31(10):1320-1335. (PMID: 32745693)
JCO Glob Oncol. 2020 Aug;6:1248-1257. (PMID: 32755479)
Lancet Microbe. 2020 May;1(1):e12. (PMID: 32835324)
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):520-522. (PMID: 32541960)
JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102. (PMID: 33875976)
Public Health Pract (Oxf). 2020 Nov;1:100038. (PMID: 34173573)
Clin Transl Oncol. 2020 Dec;22(12):2364-2368. (PMID: 32449128)
Target Oncol. 2020 Jun;15(3):249-259. (PMID: 32445083)
Int J Cancer. 2021 Jan 15;148(2):363-374. (PMID: 32683687)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Int J Infect Dis. 2020 Oct;99:47-56. (PMID: 32721533)
معلومات مُعتمدة: K01 TW011481 United States TW FIC NIH HHS; K08 CA230170 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20210310 Date Completed: 20210701 Latest Revision: 20240401
رمز التحديث: 20240401
مُعرف محوري في PubMed: PMC8081536
DOI: 10.1200/GO.20.00569
PMID: 33689484
قاعدة البيانات: MEDLINE
الوصف
تدمد:2687-8941
DOI:10.1200/GO.20.00569